REG - Hellenic Dynamics - Appointment to Development Team

Hellenic DynamicsAnnouncement

26/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230126:nRSZ8951Na&default-theme=true

RNS Number : 8951N  Hellenic Dynamics PLC  26 January 2023

26 January 2023

 

Hellenic Dynamics plc

("Hellenic Dynamics" or the "Company")

 

Appointment of Carl Haffner to Medical Cannabis Cultivation Team

 

London, 26 January 2023: Hellenic Dynamics plc (LSE: HELD) is pleased to
announce the appointment of Carl Haffner as part of Hellenic Dynamics'
development team. Carl is an industry expert having been the Co-founder and
Chief Operations Officer of UK firm Avida Global Ltd and Chief Executive
Officer of Colombian based Avida Global SAS, a vertically integrated cannabis
business.

 

Starting from a greenfield site, Avida Global went on to create a large-scale
medical cannabis cultivation and extraction facility in Colombia achieving all
necessary certifications including ISO, GACP & EU-GMP.

Carl left Avida Global in September 2022 and has remained active in the
industry as a medical cannabis consultant.

 

Hellenic Dynamics is a medical cannabis cultivator specifically focused on the
cultivation and supply of tetrahydrocannabinol ("THC") dominant strains of
medical cannabis flowers destined for the rapidly growing medical cannabis
markets across Europe. In December 2022, Hellenic Dynamics became the first
medical cannabis cultivator to list on the London Stock Exchange's main market
for listed securities.

 

Davinder Rai, CEO of Hellenic Dynamics, commented:

"As a seasoned medical cannabis industry expert I am delighted that Carl has
joined our team. Having previously successfully established an EU-GMP
cultivation facility, his appointment will provide additional support to
ensure our targets are met."

 

Carl Haffner, commented:

"I am delighted to become part of the Hellenic Dynamics team and am excited by
the prospects of establishing, in Greece, what could become one of Europe's
leading large-scale medical cannabis cultivation facilities."

 

The Directors of the Company accept responsibility for the content of this
announcement.

 

Enquires:

 

Hellenic Dynamics plc                                 +44
(0)20 3818 7850

Davinder Rai
 
davinder@hellenicdynamics.com

 

Cairn Financial Advisers LLP

Emily Staples / Jo Turner                             +44 (0)20
7213 0880

 

Peterhouse Capital

Lucy Williams / Charles Goodfellow             +44 (0)20 7469 0930

 

J&H Communications

George Hudson
 +44 (0)7803 603130

About Hellenic Dynamics plc

 

Founded in 2019, Hellenic Dynamics is specifically focused on the cultivation
and supply of THC ("tetrahydrocannabinol") - dominant strains of medical
cannabis flowers, destined for the growing medical cannabis markets
across Europe. Hellenic Dynamics' core strategy is to develop and operate its
40,000 square metre active cultivation licence from its 195,506 square metre
facility located near Thessaloniki in Northern Greece. In full production,
Hellenic Dynamics is capable of producing over 54,000 kg of dried flowers per
annum.

 

Hellenic Dynamics will take advantage of its relatively low cost base
resulting from a comparatively low cost of power, having its own running
water supply and the labour rates for skilled and semi-skilled labour in
Northern Greece.

 

25 European countries now allow medical cannabis via prescription and the
European cannabis market is expected to reach €43.3 billion per annum by
2027. Sales of Hellenic Dynamics' dried THC-dominant cannabis flowers and
extracts are initially intended for export into Europe's largest market -
Germany, in addition to other European markets including domestically in
Greece.

 

As the first medical cannabis cultivator to obtain a listing on the main
market for listed securities of the London Stock Exchange, Hellenic is
significantly different to the number of CBD (Cannabidiol) related companies
that have appeared over the recent years. Hellenic Dynamics cultivates
THC-dominant medical cannabis flowers. THC-dominant medical cannabis products
are only available via a medical prescription. Medicinal cannabis has been
approved for use both in the United Kingdom and Germany, plus 23 other
European countries, for conditions including but not limited to  chronic
pain, intractable chemotherapy-related nausea, anxiety, insomnia,
Tourette's syndrome, substance use disorder, multiple sclerosis, IBS, spinal
cord treatment, lack of appetite due to HIV/AIDS, cachexia, anorexia and
glaucoma.

For further information please visit our website www.hellenicdynamics.com
(http://www.hellenicdynamics.com)

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUAGGUPWPUA